Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 11 - 20 of 34 results.

You searched for : July 2019 to July 2020.

Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Can ...

Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute Download the PDF version of Article May 22, 2020 First-in-human phase 1...

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer Download the PDF version of Article May 21, 2020 Designation follows recent U.S. Breakthrough Therapy Designations for...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer Download the PDF version of Article May 18, 2020 Refer to Designation based on...

Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR ...

Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II Download the PDF version of Article May 15, 2020 Preclinical and...

Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting

Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting Download the PDF version of Article May 13, 2020 Research data from the pivotal phase 2...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer Download the PDF version of Article May 11, 2020 Designation based on data from pivotal...

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Tr ...

Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer Download the PDF version of...

Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patie ...

Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan Download the PDF version of Article...

ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic ...

ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Download the PDF version of Article March 25, 2020 Approval based on the pivotal...

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint Download the PDF version of Article January 27, 2020 Trial met primary endpoint of objective response rate and...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...